Oropharyngeal Squamous Cell Carcinoma Clinical Trial
Official title:
A Prospective Cohort Study to Determine Specific Volatile Organic Compounds Present in Breath Samples of Patients With Oral Cavity or Oropharyngeal Squamous Cell Carcinoma Using Gas Chromotography-mass Spectrometry
In this study the Investigators aim to determine specific volatile compounds present in breath samples of patients with oral cavity or oropharyngeal squamous cell carcinoma before and after tumour resection or before and after chemotherapy +/- radiotherapy using gas chromotography-mass spectrometry. The Investigators hypothesize that study participants with a tumour will display a distinct set of volatile organic compounds than can serve as potential cancer biomarkers.
Head and neck cancer diagnosis is devastating as it frequently disrupts one's ability to
communicate, swallow and breathe. Each year, physicians diagnose approximately 650,000 cases
of head and neck cancer worldwide. Many people with head and neck cancer have their cancer
detected late, and this can result in a poor clinical outcome. One strategy to improve the
clinical outcomes for people with a head and neck cancer is to develop a non-invasive
screening assay using breath biomarkers. Such a diagnostic tool will identify at-risk
individuals early, and potentially offer improved and cost-effective treatment.
The idea of using human breath samples to detect cancer began with the observation that dogs
can be trained to "sniff out" certain types of cancers from urine and blood. Since then the
presence of various volatile organic compounds from many types of cancers, including: lung,
skin, breast, prostate, and bladder have been characterized. These studies are ongoing, but
promise to revolutionize the way physicians screen cancer in the future.
In this pilot study, the Investigators aim to determine specific volatile organic compounds
present in breath samples of patients with oral cavity or oropharyngeal cancer before and
after tumor resection, or before and after definitive chemotherapy/radiotherapy. As head and
neck cancer can result in significant functional deficit, early detection is the key to
improving clinical outcome. Much anecdotal evidence exists for the presence of distinct odor
emissions from the tumor bed of head and neck cancer patients. Therefore, the identification
of specific volatile organic compound to head and neck cancer will undoubtedly lead to a
novel, cost-effective screening strategy for early detection of head and neck cancer.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06174428 -
Validity of Viome's Oral/Throat Cancer Test
|
||
| Recruiting |
NCT05098119 -
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
|
Phase 2 | |
| Suspended |
NCT03952585 -
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT03618134 -
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03421470 -
Docetaxel and Radiation Therapy in Treating Patients With HPV Positive Oropharynx Cancer
|
Phase 3 | |
| Completed |
NCT06314711 -
Ex Vivo 3D-ultrasound for Oropharyngeal Cancer
|
N/A | |
| Completed |
NCT04572100 -
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06055868 -
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
|
||
| Recruiting |
NCT05522881 -
The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan
|
||
| Recruiting |
NCT04222543 -
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging
|
Phase 2 | |
| Recruiting |
NCT04564989 -
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
|
||
| Active, not recruiting |
NCT04965792 -
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
|
||
| Recruiting |
NCT06356272 -
Oropharynx (OPX) Biomarker Trial
|
||
| Active, not recruiting |
NCT01874171 -
Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC
|
Phase 3 | |
| Recruiting |
NCT05333523 -
Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.
|
Phase 3 | |
| Completed |
NCT03618654 -
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
|
Early Phase 1 | |
| Recruiting |
NCT04801472 -
Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)
|
N/A | |
| Active, not recruiting |
NCT03410615 -
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
|
Phase 2 | |
| Recruiting |
NCT05268614 -
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05582590 -
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
|
Phase 1 |